Format

Send to

Choose Destination
Ann Dermatol. 2018 Aug;30(4):441-450. doi: 10.5021/ad.2018.30.4.441. Epub 2018 Jun 28.

An Open Label, Multi-Center, Non-Interventional Post-Marketing Surveillance to Monitor the Safety and Efficacy of ALTARGO® (Retapamulin) Administered in Korean Patients According to the Prescribing Information.

Author information

1
GlaxoSmithKline, Seoul, Korea.
2
Department of Dermatology, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea.
3
Department of Dermatology, CHA University School of Medicine, Pocheon, Korea.
4
Department of Dermatology, Hanyang University College of Medicine, Seoul, Korea.

Abstract

Background:

With the approval of topical retapamulin ointment in 2011, it was officially required to conduct a post-marketing surveillance (PMS) study to obtain further data of its safety profile and effectiveness, in accordance with the requirement of the Korean Ministry of Food and Drug Safety (MFDS).

Objective:

This study had prospectively designed to monitor safety and tolerability with the effectiveness of topical retapamulin in clinical practices.

Methods:

Open label, multi-center, non-interventional observational study was done from May 2011 to October 2015. All subjects had bacterial skin infections of locally approved prescribing information accordingly. The study mainly focused on safety issues in the local target population (3,612 eligible subjects). And, drug effectiveness was also evaluated by physicians.

Results:

The incidence of adverse events (AEs) and adverse drug reactions (ADRs) were 2.53% and 0.97%, respectively. In terms of the incidence of unexpected AEs and ADRs, 1.45% and 0.33%, and for the incidence of serious AEs, 0.28%, whereas no serious ADRs reported. And, the effectiveness of topical retapamulin rate was 96.1% (1,697 of total 1,765 subjects).

Conclusion:

Topical retapamulin is to be well-tolerated and effective in patients with bacterial skin infections of locally approved prescribing information.

KEYWORDS:

Anti-bacterial agents; Product surveillance; Skin diseases; infection; postmarketing

Conflict of interest statement

CONFLICTS OF INTEREST: Woosung Hong and Yil-Seob Lee are employees of GlaxoSmithKline and own company shares, which had no influence on the present work. The other authors have nothing to disclose. All listed authors meet the criteria for authorship set forth by the International Committee for Medical Journal Editors.

Supplemental Content

Full text links

Icon for Korean Dermatological Association Icon for PubMed Central
Loading ...
Support Center